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CORRESPONDENCE
Amoxicillin for the secondary 
prevention of rheumatic fever in 
children not allergic to penicillin
To the Editor: In October 2014, a communication from the 
Department of Health substituted azithromycin for erythromycin for 
penicillin-allergic patients. This was for certain conditions including 
acute rheumatic fever and prophylaxis of rheumatic fever. 
It has recently been suggested that owing to the challenges with 
the availability of oral penicillin, azithromycin should be used as a 
penicillin substitute for patients who are not allergic to penicillin.
In our opinion it is inappropriate to substitute a macrolide for 
another form of penicillin (amoxicillin) in this situation. The 
primary reason is that despite many decades of use, there is 
no significant group A beta-haemolytic streptococcal (GABHS) 
resistance to penicillin. There are, however, increasing reports of 
GABHS resistance to macrolides, and azithromycin in particular.[1-4]
A previously reported randomised trial[5] of 125 mg phenoxy-
methylpenicillin (pen VK) or amoxicillin given three times a day 
for 10 days to children with GABHS pharyngitis demonstrated 
that the recurrence of the original GABHS within 21 days after 
the end of therapy was higher with pen VK (20%) than with 
amoxicillin (13%). The geometric mean minimum inhibitory 
concentrations for amoxicillin and pen VK against 88 isolates 
of GABHS were 0.008 and 0.009 μg/mL, respectively. The mean 
concentrations of amoxicillin and pen VK in sera after 125 mg 
doses were 3.86 µg/ mL and 1.74 μg/ mL, respectively. In this 
study, therefore, amoxicillin was active against Gram-positive 
organisms at an inhibitory level similar to that of pen VK, but 
had higher blood levels. This study suggests that amoxicillin is 
probably at least as good as pen VK for the treatment of GABHS 
pharyngitis.
We therefore recommend, as per the South African Essential 
Drugs List, benzathine penicillin 600 000 units for children <30 kg 
and 1.2 million units for children ≥30 kg by intramuscular injection 
every 28 days for the secondary prevention of rheumatic fever. If it is 
not advisable to use an intramuscular form of penicillin (for example 
with a patient on warfarin), then in the absence of pen VK and in 
the absence of penicillin allergy, children weighing <20 kg should be 
given amoxicillin 125 mg twice daily, and children weighing ≥20 kg 
given 250 mg twice daily. 
There is no defined azithromycin paediatric dosage for the secondary 
prevention of rheumatic fever in penicillin allergy. Azithromycin 
has however been dosed long term in clinical trials in children with 
cystic fibrosis.[6-8] There is no consensus on the dosage, but there is 
some support[6-9] for 250 mg once daily (<40 kg) or 500 mg once daily 
(≥40 kg) three times a week (Monday, Wednesday and Friday). 
We recommend that azithromycin is used for the secondary 
prevention of rheumatic fever only in children who are allergic to 
penicillin and is dosed 250 mg (<40 kg) or 500 mg (≥40 kg), once a 
day three times a week (Monday, Wednesday and Friday).
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